Lilly's Prozac era (1987)
Lilly launched Prozac, the first blockbuster in a new class of antidepressants known as SSRIs. It made depression treatment mainstream and became one of the most prescribed drugs in the world.
Prozac reshaped psychiatry and generated billions in sales for Lilly through the 1990s.
Patents expired and big drugmakers, Lilly included, largely retreated from risky brain-drug research for years.
The AtaiBeckley deal marks Lilly returning to the depression market it once dominated, now through a psychedelic instead of a daily pill.
